摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-methoxyphenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one

中文名称
——
中文别名
——
英文名称
2-(4-methoxyphenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one
英文别名
2-(4-Methoxyphenyl)-3,5-dihydropyrido[2,3-b][1,4]diazepin-4-one
2-(4-methoxyphenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one化学式
CAS
——
化学式
C15H13N3O2
mdl
——
分子量
267.287
InChiKey
IEHYULNMBLDMPN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    63.6
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    N3-[1-(4-methoxyphenyl)-3-oxo-4,4,4-trichlorobut-1-en-1-yl]-2,3-diaminopyridine 在 sodium methylate 作用下, 以 甲醇 为溶剂, 反应 24.0h, 生成 2-(4-methoxyphenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one
    参考文献:
    名称:
    3的特异合成ħ -吡啶并[2,3- b ] [1,4]二氮杂-4(5 ħ) -酮通过卤仿用的隔离反应Ñ 3 [3-氧代-4,4,4- trichloroalk - -1-烯-1-基] -2,3-二氨基吡啶中间体
    摘要:
    一系列新的类似的中间体的合成Ñ 3 - [1 -烷基(芳基/杂芳基)-3-氧代- 4,4,4- trichloroalk -1-烯-1-基] -2,3-二氨基吡啶和Ñ 2 - (甲磺酰基)[氯3 CC(O)CH CRNH(C 5 H ^ 3 N)NHY],其中R = H中,Me,C 6 H ^ 5,4-FC 6 H ^ 4,4-CLC 6 ħ 4, 4- BRC 6 ħ 4,4-CH 3 C ^ 6 ħ 4,4-OCH 3 C ^ 6 ħ 4据报道,有4,4'-联苯,1-萘基,2-噻吩基,2-呋喃基,且Y = H,SO 2 Me。从第一系列三氯乙酰基烯胺的分子内环化反应获得的新的相应系列的2-芳基/杂芳基-3 H-吡啶并[2,3- b ] [1,4]二氮杂-4-4(5 H)- 4-甲氧基-1,1,1-trichloalk-3-en-2-ones与还证明了在温和条件下的2,3-二氨基吡啶。J
    DOI:
    10.1002/jhet.89
点击查看最新优质反应信息

文献信息

  • The first synthesis of dihydro-3H-pyrido[2,3-b][1,4]diazepinols and a new alternative approach for diazepinone analogues
    作者:Helio G. Bonacorso、Rogerio V. Lourega、Everton D. Deon、Nilo Zanatta、Marcos A.P. Martins
    DOI:10.1016/j.tetlet.2007.05.072
    日期:2007.7
    The first synthesis of a series of 2-aryl(heteroaryl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b][1,4]diazepin-4-ols, where aryl = C6H5, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-CH3C6H4, 4-OCH3C6H4, 4,4′-biphenyl, 1-naphthyl and heteroaryl = 2-thienyl, 2-furyl obtained from the direct cyclocondensation reaction of 4-methoxy-1,1,1-trifluoroalk-3-en-2-ones with 2,3-diaminopyridine in 54–71% yield, is reported
    一系列2-芳基(杂芳基)-4-三氟甲基-4,5-二氢-3 H-吡啶并[2,3- b ] [1,4]二氮杂-4-醇的首次合成6 ħ 5,4-FC 6 H ^ 4,4-CLC 6 ħ 4,4- BRC 6 ħ 4,4-CH 3 C ^ 6 ħ 4,4-OCH 3 C ^ 6 ħ 4由4-甲氧基-1,1,1-三氟烷-3-烯-2-酮与2,2-甲氧基的直接环缩合反应获得的4,4'-联苯,1-萘基和杂芳基= 2-噻吩基,2-呋喃基据报道3-二氨基吡啶的产率为54-71%。从4-甲氧基反应合成一系列2-芳基(杂芳基)-3 H-吡啶并[2,3- b ] [1,4]二氮杂-4-4(5 H)-的另一种有效的替代方法还报道了带有2,3-二氨基吡啶的-1,1,1-三氯代烷基3-en-2-one,产率为54-70%。
  • COMPOSITIONS AND METHODS RELATING TO HINDERING DOT1L RECRUITMENT BY MLL-FUSION PROTEINS
    申请人:The Regents of the University of Michigan
    公开号:US20150368300A1
    公开(公告)日:2015-12-24
    The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia.
  • US9862746B2
    申请人:——
    公开号:US9862746B2
    公开(公告)日:2018-01-09
  • [EN] COMPOSITIONS AND METHODS RELATING TO HINDERING DOT1L RECRUITMENT BY MLL-FUSION PROTEINS<br/>[FR] COMPOSITIONS ET MÉTHODES EMPÊCHANT LE RECRUTEMENT DE DOT1L PAR LES PROTÉINES HYBRIDES MLL
    申请人:UNIV MICHIGAN
    公开号:WO2014127191A1
    公开(公告)日:2014-08-21
    The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia.
  • Regiospecific synthesis of 3<i>H</i>-pyrido[2,3-<i>b</i>][1,4]diazepin-4(5<i>H</i>)-ones<i>via</i>haloform reaction with the isolation of<i>N</i><sup>3</sup>-[3-oxo-4,4,4-trichloroalk-1-en-1-yl]-2,3-diaminopyridine intermediates
    作者:Helio G. Bonacorso、Rogério V. Lourega、Liliane M. F. Porte、Everton D. Deon、Nilo Zanatta、Alex F. C. Flores、Marcos A. P. Martins
    DOI:10.1002/jhet.89
    日期:2009.7
    2-aryl/heteroaryl-3H-pyrido[2,3-b][1,4]diazepin-4(5H)-ones obtained from intramolecular cyclization reaction of the first series of trichloroacetyl enamines or from the direct cyclocondensation reaction of 4-methoxy-1,1,1-trichloalk-3-en-2-ones with 2,3-diaminopyridine, under mild conditions, is also demonstrated. J. Heterocyclic Chem., (2009).
    一系列新的类似的中间体的合成Ñ 3 - [1 -烷基(芳基/杂芳基)-3-氧代- 4,4,4- trichloroalk -1-烯-1-基] -2,3-二氨基吡啶和Ñ 2 - (甲磺酰基)[氯3 CC(O)CH CRNH(C 5 H ^ 3 N)NHY],其中R = H中,Me,C 6 H ^ 5,4-FC 6 H ^ 4,4-CLC 6 ħ 4, 4- BRC 6 ħ 4,4-CH 3 C ^ 6 ħ 4,4-OCH 3 C ^ 6 ħ 4据报道,有4,4'-联苯,1-萘基,2-噻吩基,2-呋喃基,且Y = H,SO 2 Me。从第一系列三氯乙酰基烯胺的分子内环化反应获得的新的相应系列的2-芳基/杂芳基-3 H-吡啶并[2,3- b ] [1,4]二氮杂-4-4(5 H)- 4-甲氧基-1,1,1-trichloalk-3-en-2-ones与还证明了在温和条件下的2,3-二氨基吡啶。J
查看更多

同类化合物

氯吡卓醇 利喷西平 丙吡西平 N-[(4-苯基-2,3,4,5-四氢-1H-吡啶并[2,3-b][1,4]二氮杂卓-2-基)甲基]苯甲酰胺 N-[(4-苯基-2,3,4,5-四氢-1H-吡啶并[2,3-b][1,4]二氮杂卓-2-基)甲基]乙酰胺 9-叠氮基-11-乙基-6-甲基吡啶并[3,2-c][1,5]苯并二氮杂卓-5-酮 5-甲基-11-(甲磺酰)-5,11-二氢-6H-二吡啶并[3,2-b:2',3'-e][1,4]重氮基庚英-6-酮 5,11-二氢-4-甲基-6H-二吡啶并[3,2-b:2',3'-e][1,4]二氮杂卓-6-酮 4-苯基-2-氧代-5-(2-(4-甲基哌嗪-1-基)乙酰基)-1H-四氢吡啶并[2,3-b][1,4]二氮杂卓 4-苯基-1,3,4,5-四氢-2H-吡啶并[2,3-b][1,4]二氮杂卓-2-硫酮 4-(吗啉-4-基甲基)-1H-吡啶并[2,3-e][1,4]二氮杂卓-2,3,5(4H)-三酮 4,5-二氢-1H-吡啶并[2,3-E][1,4]重氮基庚英-3(2H)-酮 3-苯基-2-氧代-5-(2-(4-甲基哌嗪-1-基)乙酰基)-1H-四氢吡啶并[2,3-b][1,4]二氮杂卓 3-(乙酰氧基)-7-氯-5-(2-氯苯基)-1,3-二氢-2H-吡啶并[3,2-e]-1,4-二氮杂卓-2-酮 3,4,6,7-四氢-10-氯-1-苯基-8H-吡啶并[3,2,1-jk][1,4]苯并二氮杂卓-4,8-二酮 2-甲基-5-(2-吗啉-4-基乙基)-3,5-二氢-4H-吡啶并[2,3-b][1,4]重氮基庚英-4-酮盐酸 1OH-吡啶并(3,2-d)噻吩并(3,2-e)(1,4)-重氮基庚英-10-酮,4,9-二氢-4-((4-甲基-1-哌嗪基)乙酰基)-,盐酸盐 11-(N-甲基六氢烟酰基)-6,11-二氢-5H-吡啶并(2,3-b)-1,5-苯并二氮杂卓-5-酮 1-(5-甲基-3,4-二氢-2H-吡啶并[2,3-B] [1,4]二氮杂-1-基)乙酮 7,7a,8,9-tetrahydro-5-methyl-5H-pyrido<2,3-b>pyrrole<1,2-d><1,4>diazepin-6,10-dione 2-(3-butoxyphenyl)-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone (S,E)-N-methyl-3-(2-methyl-3-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-((3-methylbenzofuran-2-yl)methyl)acrylamide trifluoroacetic acid salt 4-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-d][1,3]diazepin-8-yloxy)butyl methanesulfonate 8-p-tolyl-6,7,9,14,15,16-hexahydroquinoxalino[1,2-a]pyrrolo[2,3-b][1,5]pyridodiazepin-6,7,15-trione 2-(2-furyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methylphenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-phenyl-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(2-thienyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-bromophenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-fluorophenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methoxyphenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methoxyphenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(4-fluorophenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(1-naphthyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 2-(2-furyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 2-(4-bromophenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(2-thienyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 8-chloro-1-methyl-1,2,3,4-tetrahydro-5H-pyrido[2,3-e][1,4]diazepin-5-one 2,3-dihydro-3-hydroxyimino-1-methyl-5-phenyl-1H-pyrido[4,3-e]-1,4-diazepine-2-one 7a,8,9,10-tetrahydro-5-methyldipyrido<2,3-b:1,2-d><1,4>diazepin-6,11(5H,7H)-dione 1-phenyl-2-{(Z)-(4RS)-4-(3-bromo-4,5-dimethoxyphenyl)-1,3,4,5-tetrahydro-2H-pyrido[2,3-b][1,4]diazepin-2-ylidene}-ethanone (+/-)-(R,R)-2-chloro-5-methyl-1,6a,7,8,9,10,10a,11-octahydrobenzo[b]pyrido[2,3-e][1,4]diazepin-4-one (E)-N-methyl-N-((3-methylbenzo[b]thiophen-2-yl)methyl)-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylamide 2-(3-Methoxyphenyl)-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone 8-Bromo-1,3-dihydro-4,9-dimethyl-2H-pyrido[2,3-b][1,4]diazepin-2-one 5,13-Dimethyl-7,11-diazoniatricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaene 5-(2-Morpholin-4-yl-ethyl)-2-phenyl-3,5-dihydro-pyrido[3,4-b][1,4]diazepin-4-one 4,9-dihydro-10H-pyrido[3,2-b]thieno[3,2-e][1,4]-diazepin-10-one (10S)-11-acetyl-10-(2,4-dichloro-phenyl)-7,7-dimethyl-5,6,7,8,10,11-hexahydro-3,5,11-triaza-dibenzo[a,d]cyclohepten-9-one (10R)-11-acetyl-10-(2,4-dichloro-phenyl)-7,7-dimethyl-5,6,7,8,10,11-hexahydro-3,5,11-triaza-dibenzo[a,d]cyclohepten-9-one